Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety/pharmacology-related claims are partially supported (liver metabolism; hepatic impairment effects; hepatic impairment clearance/half-life lengthening). However, key claims about the specific half-life value and routine multiple-times-per-day dosing are not supported by the provided label excerpts, and the label excerpts do not establish the stated dosing frequency rationale.
Category Scores
Accurate Statements
Buspirone is processed by the liver.
Label (Section 8): “Buspirone is metabolized by the liver…”
People with significant liver impairment may have higher drug exposure from buspirone.
Label (Section 8): pharmacokinetic study showed “increased plasma levels” and “lengthened half-life” in impaired hepatic… function.
In people with significant liver impairment, buspirone clearance may be affected (i.e., how quickly it clears).
Label (Section 8): “lengthened half-life” in impaired hepatic… function (consistent with reduced clearance, but the label excerpt does not explicitly use the word “clearance”).
Unsupported Statements
Buspirone has an elimination half-life of about 2 to 3 hours.
The provided label excerpts state a “lengthened half-life” in impaired hepatic/renal function but do not provide a baseline half-life value of 2–3 hours.
Dosing is often adjusted based on clinical response and tolerability in people with significant liver impairment.
The provided label excerpt (Section 8) does not provide any dosing adjustment language for hepatic impairment; it only states administration cannot be recommended in severe impairment.
With a half-life around 2 to 3 hours, buspirone is typically taken multiple times per day to maintain steady blood levels.
The provided label excerpts do not state dosing frequency or justify it based on half-life/steady-state blood levels.
With a half-life around 2 to 3 hours, buspirone is typically not taken as a single daily dose.
The provided label excerpts do not state whether buspirone is taken once versus multiple times daily.
Contradictions
Important Omissions
For severe hepatic impairment, the label excerpt says administration cannot be recommended.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about specific half-life and dosing frequency in hepatic impairment could mislead dosing decisions; however, the core hepatic impairment directionality (increased plasma levels/lengthened half-life) is consistent with the excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several key pharmacokinetic and dosing-frequency statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or qualify the unstated baseline half-life (2–3 hours) and dosing frequency claims; align hepatic impairment statements to the excerpted language (increased plasma levels/lengthened half-life and that administration cannot be recommended in severe hepatic impairment).